News Releases

$

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Hero Chart

Mirum to host an investor call on September 29, 2021 at 4:30 p.m. ET FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI™
... Read More
Additional Formats
Partnership leverages Takeda’s leadership in rare disease, gastroenterology, and hepatology to advance maralixibat in a major market FOSTER CITY, Calif. & OSAKA, Japan --(BUSINESS WIRE)--Sep. 21, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Takeda Pharmaceutical Company Limited (
... Read More
Additional Formats
- Marketing Authorization Application for treatment of cholestatic disease in Alagille syndrome submitted. - Natural history analysis shows significant improvement in event-free survival and transplant-free survival. - PFIC regulatory strategy in Europe to focus on results of MARCH-PFIC Phase 3
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on September 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 87,500 shares of common stock
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 2, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in five investor conferences taking place virtually throughout the month of September. Citi 16 th Annual BioPharma Virtual Conference September 10, 2021 Format:
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 19, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of industry veteran William C. Fairey to its Board of Directors. Mr. Fairey brings to Mirum significant experience in establishing commercial organizations within public
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,200 shares of common stock to
... Read More
Additional Formats
- NDA for maralixibat for cholestatic pruritus in Alagille syndrome under priority review; PDUFA date is September 29, 2021 - Commercial preparations complete in anticipation of U.S. launch of maralixibat in ALGS - Conference call to provide business update today, August 5 at 1:30 p.m.
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jul. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that the company will report financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021 . That same day, Mirum will host a conference call and audio webcast at
... Read More
Additional Formats
- GC Pharma to lead development and commercialization in South Korea - Mirum seeks to expand global availability of maralixibat in rare liver diseases FOSTER CITY, Calif. & YONGIN, South Korea --(BUSINESS WIRE)--Jul. 26, 2021-- Mirum Pharmaceuticals, Inc.
... Read More
Additional Formats